# Phase I Safety Study of DMXAA in Refractory Tumors

> **NCT00856336** · PHASE1 · COMPLETED · sponsor: **Antisoma Research** · enrollment: 15 (actual)

## Conditions studied

- Refractory Tumors

## Interventions

- **DRUG:** DMXAA

## Key facts

- **NCT ID:** NCT00856336
- **Lead sponsor:** Antisoma Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2009-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00856336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00856336, "Phase I Safety Study of DMXAA in Refractory Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00856336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*